ATBECHDEDKESFRGBGRITLILUNLSEMCPT................................................JDIM360 (Ver 1.5 21 Nov 2005) - 2999001/00879596CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120070523W172 73deBibliographieenBibliographyfrBibliographieEP98201818.6199205142001021620031030enenen37069119910514IS37069119910731IS1829219920213DK2007052320072119981125199848200608162006332005051820070523200721A61K 31/14 20060101AFI19980826BHEP A61K 31/405 20060101ALI19980826BHEP A61K 31/435 20060101ALI19980826BHEP A61K 31/44 20060101ALI19980826BHEP A61K 31/66 20060101ALI19980826BHEP deVerwendung von Galanthaminen zur Linderung von Benzodiazepin-NebenwirkungenenUse of galanthamines to reduce benzodiazepine side effectsfrUtilisation de galanthamines contre les effets secondaires des benzodiazepinesG. FOSTER LARSON ET AL.: "Physostigmine reversal of diazepam-induced depression." ANESTH. ANALG., vol. 56, no. 3, 1977, pages 348-352, XP002075350E. VATASHSKY ET AL.: "Mechanism of antagonism by physostigmine of acute flunitrazepam intoxication." ANESTESIOL., vol. 64, no. 2, 1986, pages 248-252, XP002075351C.D. BLITT ET AL.: "Reversal of lorazepam delirium by physostigmine." ANESTH. ANALG., vol. 54, no. 5, 1975, pages 607-608, XP002075352P.MP. LAUVEN ET AL.: "Flumazenil (Ro 15-1788) and physostigmine." RESUSCITATION, vol. 16, no. suppl., 1988, pages S41-S48, XP002075353W.E. HOFFMAN ET AL.: "Cerebrovascular and cerebal metabolic effects of physostigmine, midazolam, and a benzodiazepine antagonist." ANESTH. ANALG., vol. 65, no. 6, 1986, pages 639-644, XP002075354U.A. PANDIT ET AL.: "Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam." ANESTH. ANALG., vol. 62, no. 7, 1983, pages 679-685, XP00207535592917377.1058428519921204Snorrason, ErnirStigahlid 80105 ReykjavikISSnorrason, Ernir02526500ACF/MSSEPP82866Stigahlid 80105 ReykjavikISFairbairn, Angus Chisholm00081002Marks & Clerk 90 Long AcreLondon WC2E 9RAGBATBECHDEDKESFRGBGRITLILUMCNLPTSE20000816200033